Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
16 hedge funds and large institutions have $338K invested in Hepion Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
11% less funds holding
Funds holding: 18 → 16 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
61% less capital invested
Capital invested by funds: $864K → $338K (-$526K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$184K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23.2K |
| 3 |
Renaissance Technologies
New York
|
+$13.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.98K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$831 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$526K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.1K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$15K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$11K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$90 |
HEPA Hedge Fund Activity: Q3 2024 in Review
16 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2024, worth a combined $338K — down 61% from $864K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of HEPA and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $184K. The largest seller was Armistice Capital, exiting entirely with an estimated $526K sold.
- 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2024, down from 18 in Q2 2024.
- Funds reported $338K of Hepion Pharmaceuticals stock for Q3 2024, down 61% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q3 2024 and 5 closed out, a net change of -2 holders.
- The largest Hepion Pharmaceuticals buyer in Q3 2024 was Anson Funds Management, an estimated $184K added.
- The largest Hepion Pharmaceuticals seller in Q3 2024 was Armistice Capital, an estimated $526K sold.
Based on aggregated 13F filings for Q3 2024.